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Objectives: Differences in testosterone replacement therapy (TRT) gel products may affect
patient satisfaction, quality-of-life, and treatment response and adherence. This study inves-
tigated preferences for TRT gel in terms of formulation and administration.
Methods: 525 male adults aged 45 years and over completed a discrete choice experiment.
Respondents made repeated choices between two hypothetical testosterone gel treatments
described according to four attributes: form, ease of use, impact of use on showering/
swimming, and location/dosage of the application. Choice data were analyzed using
a latent class model.
Results: Three preference classes were identiﬁed. Respondents across all classes displayed
a preference for the gel being dispensed in smaller units with accurate dosing, waiting shorter
times after the gel application before swimming/showering, and using 2.5 gm of gel to be
applied to the inner thigh/abdomen as opposed 5 gm to shoulder/abdomen. The importance
of these characteristics differed across classes, with preference class membership predicted
by age and education level. For instance, younger men (aged 45–64 years) were more likely
to belong to a class that prioritized reduced waiting time before being able to undertake
activities. Formulation was not an important driver of choice.
Conclusions: Preferences demonstrate a predilection for TRT gel dispensed in small units
allowing precise dosing, shorter waiting time after application, and application to the inner
thigh/abdomen. However, the strength of importance of these characteristics differs between
men. This study highlights the attributes of TRT gel considered important to patient
subgroups, and which may ultimately affect treatment response, medication adherence, and
patient quality-of-life.
Keywords: testosterone replacement therapy, discrete choice experiment, patient preferences
Introduction
Testosterone deﬁciency syndrome (TDS), also known as late-onset male hypo-
gonadism, is a clinical condition marked by low levels of testosterone.1
Testosterone performs a key role in the growth and maintenance of the male
reproductive system.2 Although levels of testosterone naturally decrease as
a result of the aging process, in men with TDS serum testosterone levels fall
signiﬁcantly below the levels of young men and this can negatively affect
health-related quality of life.3 TDS is estimated to occur in over 8% of men
between the ages 50 and 79 with greater prevalence in men with obesity and in
men with a poor health status.2,4
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Symptoms associated with the condition include sexual
problems such as erectile dysfunction, delayed ejaculation,
reduced libido and lowered fertility, as well as decreased
muscular formation, cognitive dysfunction, depression,
decreased erythropoiesis (red blood cell production and
visceral obesity).2,5 These low male sex hormone levels
are, in particular, associated with metabolic and cardiovas-
cular diseases such as hypertension, mild dyslipidemia,
insulin resistance, Type 2 diabetes, and atherosclerosis.5–7
Treatment of TDS most commonly involves testoster-
one replacement therapy (TRT) and is usually considered
for patients who are persistently suffering from erectile
dysfunction and/or diminished libido and low testosterone
levels.1,4 TRT aims to increase testosterone levels in order
to minimize the symptoms associated with TDS.8 TRT can
be administered via tablets, patches, implants, injections,
or gels. Different modes of administration are associated
with differences in application site and frequency of
administration, as well as the time taken to achieve and
maintain serum testosterone levels as the desired therapeu-
tic effect.9
These differences mean that individual patient prefer-
ences for TRT play an important role in choice of treat-
ment alongside clinical judgement. Topical gel has been
shown to be preferred by most patients in the treatment of
TDS rather than injection or patches.10 Although the effec-
tiveness of treatments at reducing TDS symptoms is para-
mount, other key factors for TRT preferences include ease
of use, convenience of at-home administration (eg, in
comparison to TRT injections), product characteristics,
and treatment experience.
In addition to efﬁcacy, manufacturers of TRT gels are
becoming increasingly aware of the need to develop pro-
ducts that aim to minimize inconvenience to the patient,
thereby improving the patient experience and increasing
patient satisfaction while maintaining the level of
effectiveness.9–11
This study aimed to compare features associated with
TRT gel products using a discrete choice experiment
(DCE) to assess which attributes are of most importance
to patients.
Methods
Recruitment and data collection
A sample of 525 males aged 45 years and over was
recruited by a third-party company (Qualtrics Ltd). We
sought the perspective of men who were naive to TRT as
this would represent the choice of men who ﬁrst com-
mence treatment following diagnosis. Therefore, to avoid
biases developed by patients who have had experience of
TRT therapies, any respondents who indicated that they
had ever undertaken TRT were not eligible. As this was an
anonymized survey and no personal medical or personally
identiﬁable data were collected, this study was not sub-
mitted to an ethics review (http://www.hra-decisiontools.
org.uk). Nevertheless, informed consent was obtained
from participants, ie, the nature and aim of the study was
provided to participants prior to participation. Potential
participants were also informed that they could leave the
survey at any stage. Participants were then asked to pro-
vide their consent to participate in the study before the
survey commenced. The authors assert that all procedures
contributing to this work comply with the ethical standards
of the relevant national and institutional committees on
human experimentation and with the Helsinki Declaration
of 1975, as revised in 2008.
DCE attributes and levels
A DCE was administered as an online survey to investi-
gate preferences for the delivery of testosterone gel. In
a DCE, respondents are presented with a series of choices
between two or more alternatives and are asked to select
the alternative they prefer in each choice set. Each alter-
native is deﬁned according to a combination of attributes
and levels. The levels of the attributes are varied system-
atically across the alternatives. The relative importance of
the attribute levels and the trade-offs individuals make
when choosing one alternative over another are estimated
through regression analysis of the choice data.
The ﬁnal attributes and levels for the DCE choice sets
are described in Table 1. These were based on the results
of a pragmatic literature review12 and clinician interviews.
The DCE also included questions related to respondents’
socio-demographic characteristics and whether they had
been previously treated with testosterone.
Experimental design
Each respondent answered eight choice sets between two
testosterone gel administration alternatives, similar to that
shown in Figure 1. For each choice set, the two products
were described in terms of the same four attributes, each
of which was varied across two levels (see Supplementary
Online Material for the scenarios). This resulted in a total
of 16 possible combinations which were paired using a full
factorial fold-over design to create the 8 choice sets.13
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Data analysis
The choice data were analyzed in NLogit statistical software
(version 6, Econometric Software Inc.) using multinomial
logit and mixed logit models for preliminary analyses and
then a latent class model (LCM), ie, unobservable group
membership, for the ﬁnal analysis.6 The preferred model
was selected based on model ﬁt (minimizing the Akaike
Information Criterion, AIC). Behaviorally, the LCM essen-
tially clusters individuals in the sample to different prefer-
ence classes, thus allowing preferences across individuals in
the sample to vary between classes but restricting them to be
the same within a class.
Within each class, the utility function for the choice
model was speciﬁed as a linear additive function of the
main effects for each attribute level, as shown Equation (1).
V jð Þ ¼ β1jFormþ β2jEaseþ β3jImpact þ β4jGel (1)
In Equation (1), V(j) is the systematic (observed) utility asso-
ciated with choice j (j= Alternative A or Alternative B in each
choice set); β1–5 are the beta coefﬁcients (also referred to as
preference weights, marginal utilities, or part worths) asso-
ciated with each attribute level; and Form, Ease, Impact, Gel
are the effects coded attribute levels, as deﬁned in Table 1.
The LCM assumes that individual behavior is inﬂu-
enced by both observable attributes and latent heterogene-
ity which varies across factors which are not observed by
the researcher.14 Thus, in this case, the LCM allows pre-
ferences for testosterone treatments to vary between parti-
cipants and an assessment of associations between
participant characteristics and preference class
Product A
Form of administration The gel is provided in a single multi-dose canister
The gel is provided in multiple sachets
within a box
The gel is dispensed in large units so 
you may need to estimate your
prescribed dose
You should wait 6 hours after
administration before swimming and
showering
In routine use, 5 grams of gel (see
picture) should be applied to the
shoulders or abdomen
The gel is dispensed in small units so it
is possible to measure your prescribed
dose accurately
You should wait 2 hours after
administration before swimming and
showering
In routine use, 2.5 grams of gel (see
picture) should be applied to the inner
thigh or abdomen
Ease of use
Impact on daily activities
Level of gel required
Which product would you choose?
Product B
Product A
Question x
Product B
Figure 1 Example choice set from the discrete choice experiment.
Table 1 Discrete choice experiment attributes and levels
Attributes Levels Level codea
Form The gel is provided in a single multi-dose canister −1
The gel is provided in multiple sachets within a box 1
Ease The gel is dispensed in small units so it is possible to measure your prescribed dose accurately −1
The gel is dispensed in large units so you may need to estimate your prescribed dose 1
Impact You should wait 2 hrs after administration before swimming and showering −1
You should wait 6 hrs after administration before swimming and showering 1
Gel In routine use, 2.5 grams of gel should be applied to the inner thigh or abdomen −1
In routine use, 5 grams of gel should be applied to the shoulders or abdomen 1
Note: aThe level coded −1 was the referent level in the LCM.
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membership.15 Respondents’ characteristics were effects
coded and entered into the LCM model as potential pre-
dictors of class membership, and then removed using
a backward-step approach if they did not explain prefer-
ence heterogeneity (ie, predict class membership) at the
20%, 10%, and then 5% signiﬁcance level.
Results
Sample characteristics
Complete choice data were available for all respondents
(Table 2). More than half of respondents (76.6%) were
younger than 65 years old. Nearly half had a university
degree, diploma, or professional qualiﬁcation (42.1%) and/
or were employed in a managerial, administrative, or pro-
fessional role (45.5%).
DCE analysis
A total of 4,200 choice observations were included in the
preference model (8 choices each from 525 respondents).
The optimal LCM had three preferences classes (AIC/N
0.813). This model exhibited a better ﬁt than both an LCM
with 2 classes (AIC/N 0.900) and a mixed logit model
(AIC/N 0.838). Attempts to estimate a fourth class resulted
in identiﬁcation problems. The LCM with three classes
had a pseudo R2 of 0.42, representing an acceptable ﬁt
for a discrete choice model.
The coefﬁcients in the LCM indicate the relative strength
of preference or “preference weight” for improvements in
the attribute levels (characteristics) of a testosterone gel
treatment, for each class. Table 3 and Figures S1–S3 sum-
marize the preferences for improvements in each attribute
level. Overall, respondents across all classes preferred the
gel to be dispensed in small units with accurate dosage
measurement rather than large units requiring dose estima-
tion, waiting 2 rather than 6 hrs before swimming or show-
ering, and 2.5 grams applied to the inner thigh or abdomen
Table 2 Respondent characteristics for Discrete choice experi-
ment (N=525)
Characteristic Category n (%)
Age (years) 45–54 198 (37.71%)
55–64 204 (38.86%)
65–74 103 (19.62%)
75–84 20 (3.81%)
Education No formal qualiﬁcations 40 (7.62%)
GCSEs or equivalent 138 (26.29%)
A-levels or equivalent 126 (24.00%)
Undergraduate degree or
diploma
146 (27.81%)
Postgraduate degree or
other higher professional
qualiﬁcation
75 (14.29%)
Employment State pensioner, unemployed,
student
183 (34.86%)
Skilled, semi-, or unskilled
manual work
103 (19.62%)
Managerial, administrative, or
professional
239 (45.52%)
Table 3 Latent class model results
Choice Coefﬁcient p-Value 95% CI
Class 1 (probability of membership =0.328)
Form −0.455 0.14 [−1.056; 0.149]
Ease −2.41*** <0.001 [−3.31; −1.51]
Impact −0.502** 0.035 [−0.968; −0.036]
Gel −0.284* 0.092 [−0.615; 0.046]
Class 2 (probability of membership =0.433)
Form −0.035 0.206 [−0.090; 0.019]
Ease −0.285*** <0.001 [−0.353; −0.217]
Impact −0.241*** <0.001 [−0.303; −0.18]
Gel −0.423*** <0.001 [−0.484; −0.362]
Class 3 (probability of membership =0.239)
Form 0.612 0.291 [−0.526; 1.751]
Ease −0.367 0.201 [−0.928; 0.195]
Impact −2.96*** 0.002 [−4.794; −1.121]
Gel 0.434 0.52 [−0.888; 1.757]
Prediction of class membership according to respondent
characteristics
Class 1 (probability of membership =0.328)
Constant 0.126 0.385 [−0.158; 0.41]
Degree/diploma −0.107 0.387 [−0.348; 0.135]
Age 45–54 years −0.733** 0.032 [−1.401; −0.644]
Age 55–64 years −0.835*** 0.008 [−1.455; −0.214]
Class 2 (probability of membership =0.433)
Constant 0.434*** 0.003 [0.150; 0.718]
Degree/diploma −0.236** 0.048 [−0.47; −0.002]
Age 45–54 years −0.793** 0.020 [−1.464; −0.123]
Age 55–64 years −0.614* 0.051 [−1.223; 0.11]
Class 3 (probability of membership =0.239)
Constant Reference Class
Degree/diploma Reference Class
Age 45–54 yrs Reference Class
Age 55–64 yrs Reference Class
Notes: ***, **, * Signiﬁcance at 1%, 5%, 10% level.
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rather than 5 grams to the shoulders or abdomen (p<0.05).
However, in Class 3 only the waiting time before under-
taking activity drove choice of gel, and the strength of
importance of these characteristics varied across classes.
Approximately one third of respondents exhibited pre-
ferences consistent with Class 1 (probability of member-
ship 0.328). Preferences in this class were strongly driven
by ease of administration; this class strongly preferred the
gel to be dispensed in small units enabling accurate dos-
ing. This characteristic was approximately 5 times as
important as impact on swimming/showering and approxi-
mately 10 times as important as the location/dosage for
application of gel (which was also only signiﬁcant at the
10% level for this class).
Nearly half of respondents exhibited preferences con-
sistent with Class 2 (probability of membership 0.433).
Preferences in this class were less extreme than for the
other classes, although the location/dosage for gel applica-
tion was slightly more important than either the ease of
dispensing or the impact on swimming/showering.
Approximately one quarter of respondents exhibited
preferences consistent with Class 3 (probability of mem-
bership 0.239). Preferences in this class were strongly
driven by impact on swimming/showering; this class
strongly preferred a 2 rather than 6 hrs wait before being
able to swim/shower. None of the other characteristics
were observed to drive choice in this class.
The form through which the gel treatment is provided
(single multi-dose canister versus multiple sachets in
a box) was not observed to be signiﬁcantly associated
with choice for any class (p>0.05).
Two socio-demographic characteristics signiﬁcantly
explained class membership (age and education; p<0.05);
hence, these characteristics were included in the model
(Table 3). Respondents with preferences consistent with
Classes 1 and 2 were more likely to be older (≥65 years)
than those in Class 3. Respondents with preferences con-
sistent with Class 2 were less likely to be educated to
degree/diploma or professional qualiﬁcation level than
those in Class 3. Employment did not signiﬁcantly predict
class membership.
Discussion
This study has investigated the preferences of adult males
aged over 45 years in the UK for the formulation and
administration of testosterone gel. This population group
reﬂects those most likely to use testosterone gel for TRT;
thus, their preferences are important to inform product
design and likely market uptake. The ﬁndings suggest
adult males in this age group prefer a testosterone treat-
ment gel dispensed in small units allowing accurate dosage
measurement, a shorter waiting time after the gel applica-
tion before being able to shower or swim, and a smaller
quantity gel application in the inner thigh/abdomen rather
than larger quantity to the shoulder/abdomen. The packa-
ging form of the gel (single multi-dose canister vs multiple
sachets within a box) does not appear to be an important
consideration for men.
However, whilst the overall direction of preference for
these characteristics appears to be consistent across indivi-
duals, the strength of importance of these characteristics
varies across the sample, with three distinct preference
classes identiﬁed from the data. Perhaps most notably,
being able to wait less time before swimming or showering
after application of the gel is more likely to be a strong driver
of formulation choice for younger men, all else being equal.
These results are in line with the literature10,11 suggest-
ing that process features such as ease of use and conveni-
ence play an important role in patient preference for TRT in
addition to the alleviation of symptoms associated with low
testosterone levels. Knowledge of individual patient prefer-
ences for TRT within the clinical consultation process
should lead to better patient adherence to medication lead-
ing to an improved clinical response and ultimately to
greater symptom control and patient health-related quality
of life.10
Limitations
The ﬁndings of this DCE assumes that the hypothetical
choices respondents say they would make would actually
be made in practice, were they to require a testosterone
treatment. However, the DCE method allows an explora-
tion of preferences round the delivery of products that are
not necessarily available in the market place, which is one
of its strengths.
The preferences elicited relate only to the attributes
included in the study; there may be other testosterone
treatment characteristics, eg, effectiveness or side effects,
or comparisons such as cream and gel, time of day for
application that may be relevant for some patients but
were not included in the choice.10 The attributes included
in this study were based on the results of a literature
review12 and clinician interviews. Therefore, since the
aim of the study was to investigate preferences around
the administration and formulation a gel, these were
assumed to be equal across the choices.
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Conclusion
Men’s preferences for testosterone gel treatment are con-
sistent in exhibiting a predilection for a treatment gel
dispensed in small units with accurate dosing, a shorter
waiting time after application before being able to swim or
shower, and a smaller quantity of gel application to the
inner thigh/abdomen. However, the strength of importance
of these characteristics differs between men. This study
extends what is known about the features inﬂuencing
patient preferences of testosterone treatments.
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The gel is provided in a single multi-dose canister
The gel is dispensed in small units so it is possible to measure your prescribed dose accurately
You should wait 2 hours after administration before swimming and showering
In routine use, 2.5 grams of gel should be applied to the inner thigh or abdomen
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Figure S1 Class 1 preferences for each attribute level. For each attribute, the columns represent the marginal preference for the identiﬁed attribute level (left column) over
its alternative level (right column). Error bars represent the 95% conﬁdence intervals (Table 3).
Class 2
The gel is provided in a single multi-dose canister
0.6
0.5
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-0.4
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The gel is dispensed in small units so it is possible to measure your prescribed dose accurately
You should wait 2 hours after administration before swimming and showering
In routine use, 2.5 grams of gel should be applied to the inner thigh or abdomen
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Figure S2 Class 2 preferences for each attribute level. For each attribute, the columns represent the marginal preference for the identiﬁed attribute level (left column) over
its alternative level (right column). Error bars represent the 95% conﬁdence intervals (Table 3).
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Figure S3 Class 3 preferences for each attribute level. For each attribute, the columns represent the marginal preference for the identiﬁed attribute level (left column) over
its alternative level (right column). Error bars represent the 95% conﬁdence intervals (Table 3).
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